Encapsulation and release of rhodium(II) citrate and its association complex with hydroxypropyl-beta-cyclodextrin from biodegradable polymer microspheres.
J Pharm Sci
; 88(5): 574-6, 1999 May.
Article
in En
| MEDLINE
| ID: mdl-10229652
ABSTRACT
Rhodium(II) carboxylates and their derivatives constitute a promising class of second-generation transition metal compounds with anticancer properties. While most transition metal anticancer compounds chelate DNA and cause extensive chromosomal damage, rhodium(II) carboxylates act on the enzyme DNA polymerase alpha and hence cause minimal chromosomal damage. Rhodium(II) citrate, a recent member of the rhodium(II) carboxylate family is highly promising as an antitumor agent. However, due to its high water solubility, a high systemic dose is necessary to achieve efficacy. In this paper, we have explored the complexation of rhodium(II) citrate with hydroxypropyl-beta-cyclodextrin as a means to improve encapsulation and release kinetics from poly(dl-lactic-co-glycolic) acid (PLGA) and poly(anhydride) microspheres. We observed that complexation of rhodium(II) citrate with hydroxypropyl-beta-cyclodextrin significantly increased both the encapsulation efficiency and duration of release in both polymer systems.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polyglycolic Acid
/
Polymers
/
Rhodium
/
Lactic Acid
/
Cyclodextrins
/
Alpha-Cyclodextrins
/
Beta-Cyclodextrins
/
Antineoplastic Agents
Type of study:
Risk_factors_studies
Language:
En
Journal:
J Pharm Sci
Year:
1999
Document type:
Article
Affiliation country:
United States